A Comparative Study of the Effects of Tibolon and Hormone Replacement Therapy (HRT) on the Predictive Markers of Cardiovascular Disease in Post Menopausal Patients

Menopause is the consistent pause of menstrual blood for one year period. It is physiologically related to lesser estrogen secretion, which develops cardiovascular disease in women above 50 and is the leading cause of death (more than 50%) among them. Tibolon is a tissue specific composition with low estrogenic, progestagic and androgenic activities. These qualities have desirable effect on menopause symptoms. This study investigated the tibolon effect and compared it to estrogen and progestron (hormone replacement therapy), as predictive markers of cardiovascular diseases in postmenopausal women in Iran.

This is a clinical- analytical trial study. 140 women in their menopause period (Aged 45-60) were randomly selected and placed in three study groups. The filled the consent form and paid no expenses. The first group received 2.5 mg of Tibolon pill plus calcium D (500 mg + 200 IU). These cond group received estrogen congoga pill (0.625 mg) plus 2.5 mg medroxi progestron state along with calcium D (500 mg + 200 IU). The third group only received daily calcium D (500 mg + 200 IU). CRP serum level and plasma lipids were compared to each other at the beginning of the study and six months after the treatment. Received: 13 Jul. 2008 Last revised: 10 May 2009 Accepted: 1 Jun. 2009

In the first group, HDL, LDL cholestrole and total cholesterol, triglicride were significantly reduced compared to prior to the treatment (P< 0.05). Both methods of Tibolon and HRT increased CRP serum level. However, the increase was more significant in HRT group (P< 0.05). In the second group, the HDL cholesterol and total cholesterol decreased. Nevertheless, triglicride and CPR significantly increased (P< 0.05). On the other hand, LDL and total cholesterol and triglicride decreased significantly (P< 0.05). The intergroup comparison revealed that Tibilon had decreased triglicride, while, HRT increased it compared to the calcium group. Moreover it had decreased HDL, whereas HRT increased it compared to the control group in addition both Tibolon and HRT decreased LDL but increased CRP, similarly. The increase being more significant in the HRT group.

Since Tibolon has the same effect as HRT on the decrease of LDL and triglicride serum levels, but less increase at CRP level, it can be an adequate substitute for HRT to eliminate the complications of menopause such as cardiovascular diseases.